Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer

NCT03067051 is registered in ClinicalTrials.gov with SpectraCure AB as lead sponsor.

NCT NCT03067051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03067051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer
Lead sponsor
SpectraCure AB
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 21, 2017
Completion date
December 31, 2027
Enrollment
66 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent prostate cancer